CST compared favourably with cholinesterase inhibitors for Alzheimer's disease in terms of numbers needed to treat (NNT) [6] and the economic analysis showed that CST was likely to be cost-effective [7]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.